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                                                          ABSTRACT 
 
 
 
Breast cancer is one of the most common malignancy diagnosed in women and is the 
primary cause of cancer-related deaths in women worldwide. It is a heterogeneous group of 
diseases that have a different response, prognosis, and clinical outcomes. Estrogen, progesterone 
and HER2 negative breast cancer, known as triple negative breast cancer (TNBC), does not 
respond to hormonal therapy.  Basal-like breast cancer (BLBC) has shorter overall survival rate 
among other subtypes. Tumors sharing both TNBC and BLBC are considered less responsive to 
currently available treatment. Chemoresistance to treatment has been a challenge in cancer 
biology and force investigation toward developing new targeted therapies, which selectively 
target specific subtypes. Sphingolipid metabolites have an important physiological role in 
determining cell fate. Sphingolipid metabolites, ceramide, sphingosine, and sphingosine-1-
phosphate (S1P), are implicated in cancer. S1P exerts its functions via extracellular and 
intracellular targets. S1P synthesized inside the cell is exported outside and binds to G-protein 
coupled receptors, the sphingosine-1-phosphate receptors 1-5 (S1PR1-5). Although the 
intracellular function is not well defined, its suggested intracellular S1P promotes cell apoptosis. 
The S1P pathway has received great attention recently due its function in cell survival and death. 
This effect was reported to be concentration dependent. 
In this research, I focused on S1P effect on nine TNBC/BLBC cell lines. I examined the 
in-vitro effects of S1P on apoptosis, proliferation, and cytotoxicity in triple negative/ basal-like 
breast cancer cell lines. Moreover, I studied the co-administration of S1P with currently used 
chemotherapeutic agents in these cell lines. Data show that S1P can selectively induce cell death 
in TNBC/BLBC cell lines at a specific concentration. In this research, I found that the 
 iii 
mechanism of cell death following treatment with different S1P concentrations was mainly due 
to apoptosis. Results show that S1P leads to cell shrinkage, rounding and detachment in the nine 
TNBC/BLBC cell lines. S1P combination with doxorubicin and docetaxel at different 
concentrations shows no beneficial effect of the combination compared to the chemotherapeuitc 
agent alone. In some cell lines, the combination showed a protective effect. 
  Further studies are required to determine the mechanism by which S1P induces cell 
apoptosis, inhibits cell growth, and demonstrates lack of responsiveness in combination studies.  
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1. LITERATURE REVIEW 
    1.1 BREAST CANCER 
        1.1.1 CLASSIFICATION 
Breast cancer is the most common malignancy in women and the second most common 
cancer of all cancer incidence worldwide1. The term breast cancer includes a wide variety of 
tumors that affect the tissue of the breast. The molecular profiling of breast cancer reveals the 
heterogeneity of the disease2. Different subtypes identified by molecular profiling makes it 
more challenging to diagnose and treat these tumors. These molecular differences between 
the subtypes are reflected in clinical outcomes and responses to therapy3. 
The etiology of breast cancer is unknown. However, hereditary factors are considered 
the major determinant of individual risk4. Mutations in cancer susceptibility genes such as 
BRCA1 and BRCA2 can be used in the assessment of individuals at risk of developing breast 
cancer. Mutations in one or both genes increase the likelihood of developing breast cancer5. 
A defect in DNA repair or alteration in growth suppressor may also increase the risk of 
developing breast cancer3. The disease starts as a single cell transformation and the 
progression of a tumor depends on accumulation of these changes3.  
The breast consist of lobules, ducts, and adipose tissue6. The most common type of 
breast cancer is the ductal carcinoma, which begins in the cells of the ducts7 8. Breast cancer 
can also start in the lobules and other components of breast tissue. In-situ and invasive terms 
are used to describe how far the disease has spread. In-situ breast cancer is localized within 
the same tissue whereas invasive breast cancer implies that tumor has metastasized to 
surrounding tissue9. 
Breast tumors are classified using different systems. Each classification serves different 
purposes. Histopathology grading depends on the histological appearance of the tumor10. A 
grade of tumor compares the appearance of the breast cancer cells to the appearance of 
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normal breast tissue10. Low grade is well differentiated and high grade is poorly 
differentiated. Staging of malignant tumors (TNM) uses three factors to describe the 
prognosis of the tumor: the size of the tumor (T), lymph node involved (N), and metastasis 
(M)11. 
Receptor status is another classification of breast cancer that utilizes 
immunohistochemistry (IHC) assay to determine the presence or absence of receptors12. The 
three receptors assessed in breast cancer are estrogen receptor (ER), progesterone 
receptor (PR), and HER2/neu13. Molecular classification of breast tumors is based on 
comparing gene expression between normal and cancer cells and clusters breast carcinomas 
based on the gene expression14. 
 
1.1.2 BREAST CANCER MOLECULAR SUBTYPES 
The current molecular classification of human breast carcinoma utilizes different 
markers to assess tumors and can be used as a diagnostic tool to determine the progression of 
diseases. Molecular classification leads to further understanding of breast cancer progression. 
The introduction of microarray technology divided breast cancer to different subtypes 
associated with different clinical outcome15. It has provided a broader definition of the 
disease as a group of malignancies that share the same origin but differ in their biology. DNA 
microarray clusters breast carcinomas based on the gene expression profiles shifting the 
treatment to more specific approach guided by certain gene expression patterns16. 
 Gene expression profiling of few key proteins including estrogen receptors, (ER), 
progesterone receptor (PR), and human epidermal growth factor 2 (HER2) has led to the 
classification of breast cancer into five major molecule subtypes:  
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a) Luminal A, b) luminal B, c) human epidermal growth factor receptor 2 (HER), d) 
normal-like, and e) Triple negative/basal-like type13. Such a classification has helped in 
predicting the treatment and the prognosis of each type17. 
Luminal A subtype is estrogen receptor (ER) positive progesterone receptor (PR) 
positive, HER negative, and low expression of proliferation genes such as Ki6718. This 
subtype is the most common, comprises about 50% of all cases, and has the best prognosis19. 
Luminal B accounts for about 20% of all breast cancer cases and is considered to be more 
aggressive than luminal A5. Luminal B subtype is ER positive and PR positive and HER2 
positive or HER2 negative with high expression of Ki6719. Luminal A and B subtypes have 
gene expression patterns similar to normal cells that line the breast ducts20-22. In general, 
luminal subtypes are known to have a better prognosis, high survival rate and low recurrence 
rate compared to other subtypes19. Hormonal therapy and targeted therapy have replaced 
chemotherapy for subclasses that overexpress the corresponding receptors. Treatment options 
of luminal subtypes is based on hormone receptor (HR) targeting such as Tamoxifene23. 
HER2 subtype is known for overexpression of human epidermal growth factor receptor 
2 (HER2) genes24. This subtype of breast cancer comprises approximately 15% of all breast 
cancer cases19. HER2 subtype has a poor prognosis, and high recurrence rate. This subtype 
can be treated with targeted therapies such as trastuzumab (Herceptin)24.  
Normal-like breast tumors account for about 5–10% of all breast carcinomas19. These 
tumors are poorly characterized and have a gene expression characteristic of adipose tissue 
and basal cells18. Some studies refer to this subtype as an artifact due to the presence of some 
normal cells in the sample25. This subtype was reported to be triple negative (TN) but not 
basal-like, since it is EGFR and CK5 negative19. 
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Triple-negative/basal-like breast cancer (TNBC) defined as a group of different breast 
tumors that share the same features but are yet still poorly characterized2. Triple-negative 
breast cancer (ER-, PR-, and HER2-) has poor prognosis26. Triple-negative and basal-like 
subtypes are often used synonymously, and the term basal-like and triple-negative terms are 
used interchangeably in the literature. However, not all triple-negative tumors are basal-like, 
and not all basal-like tumors are triple-negative21. In fact, triple-negative is considered as a 
subtype of basal-like cluster27. The unclear definition may be attributed to the origin of these 
tumors since they arise from the basal layer of breast duct28. Triple-negative and basal-like 
breast cancers show aggressive clinical behavior, poor clinical outcome, and high recurrence 
rates among all subtypes29. 
 
Figure 1: Overlap between TNBC and BLBC subtypes. Abbreviations: BLBC, basal-like 
breast cancer; ER, estrogen receptor; PgR, progesterone receptor; TNBC, triple-negative 
breast cancer 
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1.1.3 TRIPLE NEGATIVE BREAST CANCER 
 
Triple negative breast cancers (TNBCs) are a group of breast cancers characterized by 
the absence of estrogen receptors (ER), progesterone receptors (PR) and HER29. 
Approximately 20% of breast cancer cases are triple negative30’31. TNBC is more common 
among young and African-American women32. 
Immunohistochemistry (IHC) methods are used for the assessment of this type of breast 
cancer. While there is an international agreement about the term triple negative the cutoff 
level is not yet standardized15. The American Society of Clinical Oncology guidelines for 
IHC testing requires that less than 1% of tumor cells with ER and PR negative to staining for 
the assessment of triple negative12. In this respect, a more standardized cutoff is required to 
improve diagnosis. Lacking (ER/PR/HER2) receptors make this subtype unresponsive to 
hormonal and antibody therapies. In clinical practice, TNBC is referred as basal tumors 
provided that TNBC do not express ER, PR, and HER2 proteins detected by IHC technique 
and hence therapeutic choices are based on IHC. However, the increased recurrence and a 
poorer prognosis provide supporting evidence of the diversity of TNBC26 33. 
 
 1.1.4 BASAL-LIKE BREAST CANCER 
Unlike TNBC, there is no international definition for Basal-Like Breast Cancer 
(BLBC)34. Human breast is composed of two cell layers, luminal cell and basal 
cell/myoepithelial35. Basal cells and luminal cells have different expression patterns of  
cytokeratins36. Myoepithelial cells express basal cytokeratins 5, 14, and 17, and myoepithelial 
associated proteins smooth muscle actin, S-100, and CD107. On the other hand, luminal cells 
express luminal cytokeratins (CKs) 7/8, 18 and 1937. BLBCs represent approximately 20% of 
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all breast cancer cases2. In addition to their expression of high molecular weight cytokeratins, 
they have high expression levels of P-cadherin, caveolin 1 and 2, nestin, CD44, and EGFR38.   
BLBC are mainly ductal carcinomas showing high mitotic index and of high grade38. 
Tumors of this type show a metastatic pattern different than luminal subtypes with 
predominance for lung and brain3. Around 80% of BLBCs lack the expression of the key 
receptors in breast cancer namely ER, PR, and  HER2 receptors19. Therefore, a large overlap 
exists between TNBC and BLBC (Figure1). Despite the discordance between the two 
subtypes, the TNBC and BLBC terms are being used interchangeably in clinical settings. 
Several studies attempted to establish a universal definition for the BLBCs. Nielsen et 
al. 38 proposed five markers to identify basal-like tumors. These markers, ER, PR, HER2, 
EGFR, and cytokratin5/6, have a high specificity and sensitivity to classify this subtype36 38. 
A worse prognosis is a common feature of BLBC subtype, and they have the same relapse 
rate as TNBC26. Identifying new therapeutic targets for TNBC/BLBC is critical because, 
despite their high response to chemotherapy, the prognosis is still poor.  
 
1.1.4.1 EPIDEMIOLOGY  
Epidemiologically, TNBCs and BLBCs are most common among younger patient, 
less than 50 years old and most prevalent in women of black decent39. Recurrence risk peaks 
between 1–3 years, which decrease after 5 years. Survival rates decline in both subtypes after 
3-5 years of diagnosis. BLBCs are associated with poor relapse-free and overall survival. 
These tumors have large size at the time of diagnosis and are more common in younger 
patients34. 
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1.1.4.2 MOLECULAR FEATURES OF TNBC/BLBC 
 
TNBC and BLBC are not single diseases. Failure of the histopathological classification 
to define the subclasses of both types leads to the use of gene expression profiling to define 
these classes. While TNBC are negative for HER2, not all BLBCs are HER2 negative. 
The basal subtypes of breast cancers are characterized by high expression of basal 
cytokeratin and genetic markers of basal epithelium40. Gene expression profiling of 172 
TNBC tumors revealed that 71% were basal-like breast cancer, and 29% were non-basal41. 
Approximately 15%–45% of TNBCs have been shown to express ER and 14% of BLBCs to 
express HER239. Approximately 90% of BLBC are triple-negative. TNBC 
immunohistochemical profile is characterized by expression of several markers including  
CK5, CK6, CK14, CK8/CK18, EGFR1, c-kit, and insulin-like growth factor receptor 
(IGFR)42,43. TNBCs have higher expression levels of CK5/6 and EGFR than luminal 
subtypes26. Poor prognosis is correlated with cytokeratin 17 and/or cytokeratin 5/6 expressing 
tumors. Basal cytokeratin expression is used as markers for basal tumors with 5/6 cytokeratin 
being considered as the most useful44. Insulin-like growth factor-II mRNA-
binding protein 3 (IMP3), which is important in RNA trafficking and stabilization, promotes 
tumor cell growth. IMP3 is expressed during embryogenesis, and few studies reported 
expression in malignant tumors45 but not in normal tissues. IMP3 expression in cancer makes 
it a strong candidate for consideration as a diagnostic marker45. The tumor suppressor genes, 
BRCAs, are involved in DNA double strand break repair46. There is strong evidence that 
BRCA1 pathway is involved in the development of a basal-like, triple-negative subtype42. 
BRCA1 mutant and TNBC share common clinical, pathologic, and molecular features. 
BRCA1 tumors are of high-grade, high occurrence in younger women, and poor prognosis, 
which led to speculation that BRCA1 is in triple-negative tumours47. The majority of BRCA1 
8 
 
breast tumors show expression of basal cytokeratins and EGFR. BRCA1 mRNA expression 
levels were found to be diminished in TNBC48. The vast majority of BLBCs and TNBCs 
have P53 mutations49. These mutations could be an explanation for poor prognosis for both 
subtypes. 
BRCA1 mutations are associated with high-risk breast cancer46. Defective BRCA1, 
which is critical for the repair of double stranded DNA, leads to accumulation of mutations in 
DNA repairing enzymes and enhanced tumor growth. BRCA1 or BRCA2 deficient tumors are 
sensitive to Poly-ADP ribosepolymerase-1 (PARP)50. PARP is a single strand break repair 
enzyme that when inhibited by (PARP-1) inhibitors leads to cell death due to the 
accumulation of these double strand DNA breaks. 
 
1.1.4.3 CLINICAL FEATURES OF TNBC/BLBC 
 
Aggressive clinical features of TNBC/BLBCs have been reported by several studies37. 
Poor clinical outcome and reduced disease-free survival compared to other types of breast 
cancer. A study carried by Dent et al. reported that the median time to death for patients with 
TNBC was 4.2 years26. The overall survival is shorter than for other breast cancers, and most 
deaths occur within the first five years after diagnosis26 38. Distant recurrence was reported to 
be higher than other breast cancer groups with local recurrence shorter in patients with TNBC 
than other breast cancer subtypes. Visceral, bone, and brain metastases have been reported to 
be higher in TNBC than other types of breast cancer28. All these results confirmed that TNBC 
has a relatively poor prognosis and less response to treatment. 
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1.1.4.4 TREATMENT OF TNBC 
 Despite the initial susceptibility of TNBCs to chemotherapy, their overall survival 
rates are low51. Compared to receptor positive subtypes, the risk of relapse is still high 
reaching peak after three years52. No specific treatments are available for TNBC with 
chemotherapy as the only option available for TNBC patients. However, efforts to identify 
targetable markers in TNBC are promising. 
 The effectiveness of chemotherapy in TNBC has been investigated by several 
studies53-55. Neoadjuvant chemotherapy response of TNBC was reported to be better than 
other breast cancer subtypes30. However, the prognosis is still poor. Taxanes, anthracycline 
and platinum-containing agents, such as cisplatin, are most frequently used in TNBC. 
However, recurrence rates are still high48. Taxanes containing an adjuvant or neoadjuvant 
regimens were found to be effective in early-stage disease56. Taxanes increased the diseases 
free survival by 87% as compared with cyclophosphamide among TNBC patients56. In 
general, there is no preferred single or combination chemotherapy specifically recommended 
for TNBC57.  
TNBC has been reported to have higher pathologic complete response (pCR) rates 
compared to HR positive breast cancer when treated with neoadjuvant chemotherapy 
receiving anthracycline or anthracycline and taxanes58. The response of TNBC to 
neoadjuvant therapy was significantly higher than other types of cancer. However, the overall 
3-year progression free survival was reported to be less than other types demonstrating the 
poor prognosis in TNBC54. Neoadjuvant therapy with the platinum-based drug in TNBC 
patients with BRCA1 mutations showed that 90% of cases had complete pathological 
responses44. Studies with other cytotoxic drugs have been also conducted. Neoadjuvant 
cyclophosphamide showed higher pCR rate in TNBC patients as compared to luminal 
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subtypes55. Neoadjuvant ixabepilone ( microtubules stabilizer ) trials demonstrated a higher 
response to HR-negative than HR-positive tumors59. This study showed greater sensitivity for 
TNBC to ixabepilone than ER+ tumors. 
Platinum-based therapies were reported to be effective in tumors with BRCA1 
mutations60. Accordingly, TNBC has demonstrated high pCR compared with non-TNBC 
patients61. However, platinum-based therapies showed no efficacy in BLBC tumors62. PARP 
is single-strand DNA break (SSB) repairing enzyme by base excision repair. Clinical studies 
using PARP inhibitors in BRCA-mutant patients are still ongoing. The combination of PARP 
inhibitor iniparib with carboplatin resulted in increased patient survival by five months60. 
Olaparib, a potent oral PARP inhibitor, was tested against TNBC tumors. Olaparib showed a 
very high response rate in TNBC tumors63. 
 Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor has been assessed in 
the TNBC54. Clinical trials on inhibition of angiogenesis in TNBC by monoclonal antibodies 
against the vascular endothelial growth factor (VEGF) receptor or VEGF receptor inhibitors 
are currently underway64.Despite the result mentioned above, TNBCs demonstrate only 
modest response to treatment and remains a challenging disease to treat.  
 
1.1.4.5 CHEMORESISTANCE IN TNBC 
 
Chemoresistance is the major problem facing cancer treatment, which accounts 
approximately for 90% of treatment failure in metastatic cancer65. Tumors not only become 
resistant to the used drug but also may develop cross-resistance to other chemotherapies. As 
mentioned above, TNBCs lack the expression of ER, PR, and HER2 receptors that make 
them unresponsive to hormonal or anti-HER2 agents. Understanding the diversity of TNBC 
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/BLBC and their molecular characteristics will help in bypassing the chemoresistance 
developed by these tumors.  
Previous studies have indicated several targets for drug resistances in TNBC51 56. 
ATP-binding cassette transporters (ABC transporters) are among most thoroughly 
investigated targets in TNBC chemoresistance. Transporters affect the ability of 
chemotherapeutic drugs to reach its proposed target. P-glycoprotein (P-gp), multidrug 
resistance-associated protein (MRP), and breast cancer resistance protein (BCRP) are the 
most common transporters involved in drug resistance in TNBC66. Decreased intracellular 
doxorubicin accumulation in TNBC was attributed to overexpression of BCRP66. P-gp was 
observed to efflux a wide range of chemotherapeutic agents67. 
Another mechanism of resistance to chemotherapy is the overexpression of β-tubulin 
III subunit which was found to be correlated to paclitaxel resistance68. β-Tubulin III together 
with α-tubulin is responsible for the formation of microtubules which is the target for 
paclitaxel related cell death69. Overexpression of β-tubulin III in TNBC51 explains why 
resistance to paclitaxel exists in some TNBC tumors. Mutations in DNA repairing enzymes 
such as topoisomerase II was correlated with chemoresistance to anthracyclines51. Alteration 
in apoptosis regulating genes such as p53 and caspase-3 were correlated with 
chemoresistance of tumors to tubulin inhibitors 70 71. 
Given these data, we can affirm that TNBC/BLBC subtypes do not all respond in the 
same magnitude to chemotherapy treatment. The response depends largely on gene 
expression of the targets mentioned above. 
 
 
12 
 
1.2 SPHINGOLIPIDS 
         1.2.1 INTRODUCTION  
 
Sphingolipids were first identified in the 1870s in brain extracts and were named after 
the Greek mythological creature, the Sphinx, because of their enigmatic nature72. 
Sphingolipids constitute a class of lipids defined by their eighteen carbon amino-alcohol 
backbones that are synthesized in the endoplasmic reticulum73. In addition to their supportive 
role in the cell membrane in eukaryotic cells, sphingolipids play a pivotal role as signaling 
molecules. Sphingolipid metabolites, ceramide, sphingosine, and shingosine-1-phosphate 
(S1P), are the major signaling sphingolipids74 75 and have been identified as a determinant of 
cell fate, which regulate cell proliferation, survival, and apoptosis76. 
The potential roles of sphingolipid derivatives have been described in different 
systems such as cardiovascular, immune, and nervous systems77. However, alteration in their  
levels were implicated in many pathophysiological disorders such as cardiovascular diseases, 
diabetes, inflammatory, and infectious diseases78. 
Sphingolipids’ role in cancer has received significant attention recently. The growing 
evidence of sphingolipid pathway involvement in carcinogenesis has been reported by several 
studies79-82. The role of sphingolipid signaling in breast cancer subtypes was reported by 
expression levels of certain enzymes involved in the metabolic pathway of sphingolipids. 
These results reflect the impact on prognosis and resistance to chemotherapy. Sphingosine -1-
Phosphate is the end metabolite of interest that draws researcher’s attention as a signaling 
molecule in disease76. 
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1.2.2 SPHINGOLIPID PRODUCTION AND METABOLISM 
 
Sphingosine is an 18-carbon amino alcohol with an unsaturated hydrocarbon chain that 
is one of the active metabolites of sphingolipid83. S1P is produced by the phosphorylation of 
sphingosine by kinase enzymes84. Sphingolipids biosynthesis starts from the cell membrane 
upon internal or external signal leading to the conversion of sphingomyelin into ceramide by 
sphingomyelin synthases73,77. Ceramide, one of the bioactive molecule in this pathway, is 
then metabolized to sphingosine by the enzyme ceramidase74 (Figure 2). 
In addition to its generation from sphingomyelin, ceramide can be synthesized de novo 
from serine and palmitate74. Sphingosine is phosphorylated by two sphingosine kinases to 
produce sphingosine-1-phosphoate (S1P)85. S1P is metabolized irreversibly by sphingosine-
1-phosphate lyase, an enzyme localized in the endoplasmic reticulum ethanolamine and 
hexadecanol86 or can be converted back to sphingosine by S1P phosphatase87.  
 S1P produced inside the cell is then exported to the extracellular environment, so it 
functions in an autocrine and paracrine manner88. Due to its polar head group, S1P is unable 
to cross the cell membrane. Studies reported the involvement of ABC transporters in this 
process89. To a lesser extent, Spinster2 transporter was also suggested as a way of S1P 
export89. A concentration gradient of S1P exists between the tissue and plasma. Plasma levels 
are higher than tissue concentrations and total plasma concentrations being much higher than 
required to activate the receptors90. S1P has been found in numerous cells with plasma 
concentration ranges from 0.2 to 0.9 µM75. It appears to bind to plasma albumin and 
apolipoprotein M90. This binding lowers the concentration of free to S1P to the level closer to 
Kd value of the receptors
91. S1P exerts its effect by binding to a particular family of G 
protein-coupled receptors (GPCRs), triggering certain intracellular and extracellular actions76, 
92. 
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As a determinant of cell fate, the three signaling molecules remain in a dynamic 
balance within the cell93. This balance is maintained by the SphK and S1P phosphatase which 
convert S1P back to sphingosine76. Ceramide and sphingosine are implicated in cell death and 
growth arrest and S1P is implicated in proliferation and survival. This balance is proposed to 
be the regulator of cell survival in response to stimuli94, 95 
 
 
   Figure 2: Production and Export of Sphingosines: biosynthesis pathway of sphinosine-1-
phosphate (S1P) production. The process starts from cell membrane sphingomyelin 
conversion to ceramide by sphingomyelinase. Ceramide can then be converted to sphingosine 
which eventually is converted to S1P by kinase enzyme. S1P can travel outside the cell and 
bind to G protein coupled receptors. 
 
1.2.3 SPHINGOSINE-1-PHOSPHATE (S1P) 
 
S1P is a lipid mediator that is involved in many physiological and pathological 
conditions mediating signaling cascades involved in cell proliferation, angiogenesis, 
apoptosis, regulating proliferation and angiogenesis89. S1P functions as a dual messenger 
signaling molecule interacting with extracellular cell surface receptors and intracellular 
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receptor as a second messenger96. Extracellular S1P acts via interaction with G-protein-
coupled receptors (S1PR1-5)97-99. Receptor studies revealed that cells express more than one 
S1P receptor type100. Upon certain stimuli, such as growth factor, cytokines or hormones, 
SphK starts the synthesis of S1P101. This production is also regulated by the intracellular 
levels of sphingolipids and sphingolipid metabolizing enzymes. SphK exists in two isoforms, 
SphK1, and SphK2102. They have varying tissue distribution, substrate specificity, and 
cellular localization. SphK1 is located in the cytosol and SphK2 is positioned in the 
nucleus103.  
 
1.2.3.1 EXTRACELLULAR FUNCTION OF S1P 
S1P regulates several cellular functions through binding to G-protein-coupled 
receptors85. S1P binds to five GPCRs, S1PR1-5, leading to a series of downstream signaling 
pathways explaining the diversity of its function100. S1PRs, like other GPCRs, activates 
different heterotrimeric G proteins. Expression levels, binding affinity and pathway activation 
are the reasons for the wide variety of actions S1P has.  
S1P regulates an ample range of cellular functions by activation of different G 
proteins. Pathway activation through coupling of S1P with its receptor varies depending on 
the receptor involved. The diversity of the signal generated is achieved by binding of the 
receptor to different alpha subunits in the G protein (Gs, Gi/o, Gq/11, and G12/13)104. This 
binding, results in various downstream cellular effects leading to activation of adenylyl 
cyclase inhibition as well as the Ras/MAP kinase cascade and (PI3 kinase)/Akt, 
phospholipase C (PLC), and small Rho GTPases105. 
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S1PR1 couples only to Gi protein regulating different cellular functions including 
migration, proliferation, survival, cell–cell contact, angiogenesis, and lymphocyte 
trafficking104. At nanomolar concentrations, S1P activates extracellular signal-regulated 
kinase (ERK) and PI3K pathways85. This binding activates a series of the downstream 
signaling pathways and eventually lead to Akt activation and therefore induction of cell 
survival and Rac activation to induce cell migration106. Gi activation also leads to Ca2+  
release from intracellular stores through activation of phospholipase C (PLC)107. Activation 
of PI3K pathway leads to a series of modulation of protein kinases Akt subsequently, leading 
to nitric oxide synthase (eNOS) activation. These series of signaling pathways produce a 
wide variety of biological functions such as angiogenesis, proliferation, and migration108,109.   
S1PR2 and S1PR3 couples to Gi, Gq, and G12/13 subunits107. Again, both receptors 
activate the Gi subunit leading PLC to induce IP3 formation and Ca2+ mobilization. However, 
they do this with different preferences110. S1PR2 activates Rho and inhibits Rac while S1PR3 
activates both Rho and Rac108. S1PR2 regulates the anti-proliferation activity of S1P111. 
Moreover, S1PR2 inhibition of Rac was shown to inhibit migration111. Differences in the 
binding preference between S1PR2 and S1PR3 lead to a different biological response. 
S1PR2 inhibits cell migration in normal and cancer cells via Rac inhibition112. 
Therefore, cells that express S1PR2 are highly susceptible to S1P treatment to prevent 
migration. Yamaguchi et al113 reported inhibition of lung metastasis in melanoma cells 
expressing S1PR2 after treatment with S1P. S1P4 couples to Gi and G13 activating PLC and 
ERK. S1P5 couples to G12 and Gi114. Their binding to these subunits produce the same 
biological actions. 
Tissue expression of S1PRs is another major determinant of its biological action. 
These receptors are expressed in different tissues. S1PR1, S1PR2, and S1PR3 are more 
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widely expressed receptors with S1PR1 being most abundant receptor among all S1PRs115. 
S1PR1 has high expression levels in the brain, cardiovascular system, kidney, and muscle 112. 
S1PR2 shows broad tissue gene expression109. Animal studies with receptor knockout models 
have revealed the important biological function of S1PRs. The importance of S1PR1 for 
vascular maturation and its important role in angiogenesis is well reported. The S1PR1 null 
mice died in utero because of defective vasculature116. 
 S1PR2 is involved in nervous system diseases117. Hearing loss and balance resulted 
from neuro-degradation in S1PR2 knockout mice118 is an example of its key role the nervous 
system. Expression levels of S1PR4 and S1PR5 are generally less than the other three 
receptors. S1PR4 is restricted to lymphoid tissue and hematopoietic cells109. S1PR5 is 
expressed mainly in CNS, namely brain, white matter tracts, oligodendrocytes75. 
S1P anti-proliferative action was reported in different studies using hepatocytes. Ikeda 
et al 119 reported that S1P exerted antiproliferative action by binding to S1PR5 and activation 
of Rho. However, no further studies reported this effect. In another study, S1PR2 seemed to 
be responsible for the anti-proliferative effect of S1P.  
Regulation of cell migration by S1P was reported in different cell lines. The migratory 
cellular response is also receptor dependent process. Overexpression of S1PR1or S1PR3 
induces cell migration120. On the other hand, S1PR2 overexpression decreased cell migration 
via Rac inhibition111. Therefore, it is more likely that the action of S1P is determined by the 
level of receptor expression. 
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1.2.3.2 INTRACELLULAR FUNCTION OF S1P 
 
In addition to its extracellular role, S1P can act on intracellular targets that are 
independent of its cell surface receptors. The exact mechanism of S1P intracellular action is 
still unknown; several studies report different targets for its intracellular action. S1P role in  
cell proliferation has been examined enormously. Promoting cell growth, survival, 
angiogenesis85 116 and migration121 are the main functions under investigation. These 
functions are associated with its extracellular G protein-coupled receptors. Regulation of S1P 
levels within the cell is an indicator for its intracellular action. However, these intracellular 
targets are not clearly elucidated.  
The presence of intracellular S1P is indicative of its intracellular function. The 
intracellular action of S1P is believed to be the opposite of its extracellular action. In yeast, 
Saccharomyces cerevisiaei, exogenous S1P has no reported affect on cell growth109. Since 
yeast do not express cell surface receptors for S1P, its function might be solely intracellular. 
Accumulation of S1P in yeast resulted in growth suppression109. Maceyka et al. reported the 
opposing function of SphK enzymes122, the two isozymes responsible for phosphorylation of 
sphingosine to give S1P123. While many studies reported the anti-apoptotic action of 
SphK1115, SphK2 was observed to suppress growth and induce apoptosis122. 
S1P formed by SphK2 inhibits histone deacetylases103. S1P produced by SphK2 
prevents the removal of acetyl groups within the histone by inhibiting the enzymatic activity 
of HDAC1 and HDAC2124. Therefore, HDAC appears to be an intracellular target for S1P. 
SphK2 is predominantly localized to the nucleus125, and its action appeared to be the opposite 
of SphK1. SphK2 was reported to be associated with growth arrest and apoptosis, and this 
action depends on cell type126. Liu et al. reported that SphK2 increased doxorubicin-induced 
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cell death127. These reports indicate SphK2’s different actions. SphK2 increases the release of 
cytochrome c into cytosol that initiate apoptosis by activation of caspase 3127. This apoptotic 
effect is receptor independent128.  
S1P was reported to induce apoptosis in different cell lines such as hMFs129, MDA-
MB321 breast cancer cell line 92, and B16 melanoma cells128. This effect was neither due to 
conversion of S1P to ceramide129 nor to its effect through cell surface receptors128. Induction 
of apoptosis by SphK2 depends on Ca2+ mobilization from internal stores where S1P is 
believed to act as a second messenger76. Additional evidence supporting the intracellular 
function of S1P is the SphK2 inhibitor that suppressed the proliferation of MDA-MB-
231 breast cancer cell line130. Although S1P was reported as an anti-apoptotic molecule, 
exogenous addition of S1P induced apoptosis that does not involve S1PR ligation, suggesting 
that S1P induced apoptosis is achieved by intracellular mechanisms109. S1PR1-3 knockout 
mice showed reductions in tumor size providing additional evidence in ruling out S1PR 
involvement in the process131. FTY720, a sphingosine analog, was reported to produce 
apoptosis by being phosphorylated with SphK2132. All previously mentioned evidence 
demonstrate that S1P has an intracellular action. 
 
 
1.2.4 SPHINGOLIPIDS AND CANCER 
 
 Involvement of sphingolipid pathways in cancer has been reported in several studies. 
Alterations in sphingolipid metabolite levels and enzyme expression in cancer have 
strengthened the association between sphingolipid pathway and pathophysiology, progression 
and treatment resistance of the disease.  
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  The role of ceramide has been studied extensively in cancer. Given its biological 
action as a proliferation inhibitor109, many studies reported its effect on inducing apoptosis in 
tumors. On the other hand, S1P plays the opposite role inducing proliferation and increasing 
resistance to chemotherapy. Moreover, sphingolipid metabolizing enzymes, especially SphK, 
are upregulated in many tumors80, consequently increasing tumor progression and metastasis. 
Plasma levels of S1P received ample attention in cancer. S1P levels were reported to be high 
in some tumors as a result of SphK1 overexpression133. S1P phosphatase and SPL are the two 
enzymes that regulate the concentration of S1P86 134. SPL overexpression was reported to 
enhance the action of cisplatin135.  
 
1.2.4.1 S1P RELATED GENE EXPRESSION IN CANCER 
 
The SphK1 expression is correlated with increased tumorigenic potential, poor 
prognosis, and shorter disease survival. SphK1 up-regulation in a variety of human tumors 
suggests its action as an oncogene102. Elevated plasma S1P levels and decreased SPL, the 
main mechanism of S1P degradation, and SPP in expression levels in tumor tissue are 
inconsistent with the role of S1P in promoting tumor growth. Down-regulation of these 
enzymes provides supporting evidence for the role sphingolipids play in tumor 
progression102. 
 
1.2.4.2 S1P EFFECT ON CELL SURVIVAL 
 
  SphK (SphK1 and SphK2) produces S1P by phosphorylation of sphingosine.  
Although the two enzymes produce intracellular S1P, they are encoded by distinct genes and 
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have different biological functions87. The oncogenic activity of SPhK1 is related to its high 
mRNA expression levels in various tumors136. S1P binding to its G-protein coupled receptor 
(S1P1−5) initiates signal transduction. Several growth are affected by S1P signaling such as 
platelet-derived growth factor, epidermal growth factor (EGF), and vascular endothelial 
growth factor (VEGF)137. 
S1P as a biomarker for cancer detection was reported in a study conducted by Nunes 
et al. The study showed that circulating S1P levels were lower in patients with prostate 
cancer compared with healthy patients, which suggests S1P levels may reflect early 
metabolic changes in prostate cancer patients and represents an early marker for progression 
of tumor. Upregulation SphK1 and S1PRs were reported in prostate cancer cells138. 
 
1.2.4.3 S1P EFFECT ON CELL PROLIFERATION  
 
Targeting the S1P pathway for cancer treatment is based on the fact that S1P 
contributes in tumorigenesis. The anti-apoptotic effect of S1P and mitogenic effect in most 
cell types is well recognized78. These effects may be dependent or independent on the S1P 
receptor as reported in S1P receptor deletion studies139. 
 
Autophagy triggered by S1P plays an important role in tumor cell survival. Metabolic 
stresses activated autophagy through S1P5 receptor and is documented in human prostate 
cancer cells. PDGF, VEGF, and TNF-α induces S1P production mediating tumor progression. 
The generated S1P interacts with S1P receptors on the cell surface of the same or a nearby 
cell and promotes tumorigenesis. This effect was further studied using prostate cancer cells 
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with high expression of SphK1140. Furthermore, SphK1 knockdown and SphK inhibition 
studies showed a reduction in tumor progression102. 
SphK1 is a critical component of EGFR signalling, which was demonstrated by 
Sarkar et al141. EGF is an important growth factor for MCF7 cell proliferation, progression, 
and invasion. This study showed the importance of SphK1 in EGFR signaling. The effect of 
SphK1 expression on EGF-induced proliferation was examined in MCF7 cell line where 
results indicate that overexpression of SphK1 protects the cell line from apoptosis and low 
levels reduced cell growth141. The results provide supporting evidence for SphK1’s critical 
role for the growth and metastasis of human breast cancer. Similar results were observed in 
prostate cancer, bladder cancer, and melanoma102. These observations indicate that SphK1's 
role in mediating survival is common to numerous malignant cell types. 
 
Decreased degradation of S1P by SPL has a similar effect to SphK1 overexpression.  
The exact role of SPL is not determined. However, several studies reported on the effect of 
low levels of SPL on decreasing apoptosis and sensitivity of chemotherapy drugs102. 
 
1.2.4.4 S1P EFFECT ON MIGRATION AND METASTASIS 
 
 Metastasis is one of the hallmarks of cancer. S1P affects cell invasion by the 
receptor-dependent mechanism. S1P1, S1P3, and S1P5 activate cell migration while 
S1P2 receptor may inhibit cell migration
142. Cell migration is initiated by degradation of 
extracellular matrix-by-matrix metalloproteinase (MMPs). This enzyme is likely to be 
overexpressed by S1P143. 
S1P mediates cell invasion by different mechanisms. These mechanisms include 
enzyme regulation and cell adhesion. Glioblastoma invasiveness is mediated by S1P through 
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the activation of plasminogen activator inhibtor-1. On the other hand, anti-migratory effects 
of S1P were observed in glioblastoma exclusively expressing S1PR2. The anti-migratory 
effect was achieved through RhoA/Rho-kinase activation102.  
 
Melanoma expressing S1PR2 cells were reported to exhibit an anti-migratory and pro-
migratory effect in the same cells expressing S1PR1143. Tumors expressing high levels of 
S1PR2 inhibited cell migration. S1PR3 expressing tumors have a positive affect on cell 
migration. These findings demonstrate the receptor dependent manner by which S1P 
mediates tumor cell migration and metastasis102 142. Ovarian cancer cell invasion was 
activated by S1P through activation of ERK and AKT pathways. Enhanced tumor cell 
migration was observed in pancreatic cancer with high expression levels of SphK1. Similar 
results were reported in breast cancer cells143. 
 
1.2.4.5 SIP EFFECT ON ANGIOGENESIS  
 
Tumor growth and metastasis are governed by angiogenesis. Angiogenesis is a crucial  
step in solid tumor metastasis and progression. Angiogenesis was stimulated by S1P 
production in-vivo and  in-vitro107. The role of S1P in angiogenesis has been reported in 
several studies. Angiogenic and tumorigenic effects of S1P was tested in-vivo and in-vitro. 
S1P induces angiogenesis by up-regulating proangiogenic growth factors, basic 
fibroblastic growth factor (bFGF) and vascular endothelial growth factor (VEGF) as well as 
cytokines implicated in angiogenesis75 144. VEGF was reported to be up-regulated by S1P in 
prostate cancer cells140. VEGF induces S1P receptor expression in bovine aortic endothelial 
cells BAEC140 145. S1P and VEGF have a synergistic effect on angiogenesis in inducing 
S1PR1145. Inhibition of SphK1 decreased VEGF-induced expression of adhesion molecules. 
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Inhibition of TNFα induced apoptosis in endothelial cells by S1P provides supporting 
evidence for its role in blood vessels proliferation143. 
S1PR1 siRNA has been reported to decrease vascular stabilization, angiogenesis and 
tumor growth in-vivo102. Expression of S1PR1 is up-regulated in the tumor vasculature during 
angiogenesis. Chae et al. described that down-regulation of S1PR1 expression with siRNA 
inhibited angiogenesis and tumor growth in-vivo. This result is in agreement with the role of 
S1P as a pro-angiogenic factor146. High expression levels of S1PRs in vascular endothelial 
cell are well known where it was originally identified, therefore, named Edg (endothelial 
differentiation gene). Lack of S1PR1 showed impaired angiogenesis in mice.116 Additionally, 
impaired angiogenesis by antisense S1PR1 oligonucleotides demonstrates the crucial role of 
S1P signaling in endothelial cells proliferation and migration147. 
Activation of S1P receptors increases production growth and pro-angiogenic factors 
such as VEGF implicating of S1P in cancer progression148. A study conducted by Watson et 
al. showed that increased S1PR expression level is associated with shorter time to recurrence 
and associated with shorter disease-specific survival times. These results provide supporting 
evidence for the role S1P plays in tumor progression149. 
  Formation of new vessels by remolding of extracellular matrix (ECM) is important for 
angiogenesis. Matrix metalloproteinase (MMPs) are involved in matrix remodeling enabling 
formation of new blood vessels. MT1-MMP is activated by S1P and has been shown to 
promote the formation of new blood vessel rat. MT1-MMP–knocked out mice showed no 
angiogenic response to fibroblast growth factor 2150 151. Lowering S1P levels using  anti-S1P 
monoclonal antibodies inhibited angiogenesis induced by VEGF and bFGF in murine 
xenograft and allograft models144. 
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The crucial role of S1P signaling in tumor angiogenesis is consistent with the 
progressive nature of tumor S1P1 expression which is strongly induced in tumor vessels as 
blockade of this pathway inhibited tumor angiogenesis. 
 
 
1.2.5 SPHINGOLIPIDS AND BREAST CANCER 
 
  Overexpression of SphK1 has been reported in stomach, lung, brain, colon152, kidney, 
and breast cancer87. (ER-) Breast cancer was found have higher expression levels of SpkK1 
than (ER+) suggesting that increased SphK1 expression has a strong association with shorter 
disease-free and disease-specific survival. 
Increased ceramide and sphingosine levels have been described in MCF-7 breast cancer 
cell line after treatment with doxorubicin leading to cell apoptosis. Overexpression of SphK1 
in MCF-7 cells strengthens the involvement of S1P in the progression of breast cancer 
subtypes. Increased SphK1 expression is associated with acquisition of resistance to 
tamoxifen leading to reduced patient survival149. S1P produced inside the cells is transported 
to the hostile extracellular environment of cancer cells. Binding of S1P to its receptors 
promotes proliferation of cancers cells as previously discussed. S1P is known to exert its 
intracellular functions, but its relevance to cancer biology is not well known98. 
 
SphK1 may promote breast, growth, and responsiveness to estrogen. The tumorigenic 
effect that SphK1 has in breast cancer cells was found to be associated with its  
overexpression153. SphK1 activation by estrogen signaling promotes estrogen-dependent 
oncogenesis154. Datta et al correlated high expression levels of SPHK1 in TNBC cells with 
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poor overall and progression-free survival. The study also correlated elevated SphK1 with 
poor response to Doxorubicin treatment155. These results were demonstrated by SphK1 
inhibition in TNBC cell lines using SKI-5C, a pharmacological inhibitor of SphK1, which in 
turn sensitized TNBC cells to doxorubicin chemotherapy155. Increased SphK1 expression in a 
variety of solid tumors brought attention to the role sphingosine plays in cancer156. In-vitro 
studies revealed the involvement of sphingosines in cancer cell proliferation, survival, and 
migration76.  
The role sphingosines have in cancer has been investigated in different studies. 
Cellular processes namely, apoptosis, proliferation, angiogenesis metastasis are regulated by 
sphingolipids in cancer. In addition to their role as a second messenger, sphingolipids alter 
cellular metabolism in normal cells. Sphingolipids metabolites, including sphingosine, 
ceramide, and S1P, provide structural and functional support to growing cells98.   
An impaired apoptotic mechanism is a hallmark of tumor cells. Normal cells initiate 
apoptosis to terminate abnormalities. Sphingolipids metabolites have proapoptotic as well as 
anti-apoptotic properties. The balance between survival and death is termed rheostat model 
where ceramide and sphingosine, the proapoptotic molecules, levels are elevated in response 
to various stimuli to initiate programmed cell death. S1P is the anti-apoptotic and initiates 
cell signals to promote cell growth and proliferation74,75, 92. 
 
1.2.5.1 SPHINGOLIPIDS AND TNBC/BLBC 
 
Triple negative breast cancer is associated with poor prognosis, tumor aggressiveness, 
and limited therapeutic options. SphK1 expression is correlated with poor prognosis that can 
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be attributed to increased levels of S1P157 leading to increased migration and 
chemoresistance87. 
SphK1 expression was found to be higher in many human tumors than in normal 
tissues78. Studies revealed that sphingosine kinase enzyme SphK1 has been associated with 
tumor lymphangiogenesis158. On the other hand, few studies indicate the opposite action of 
SphK2. Antoon et al. reported that SphK2 inhibition induced intrinsic apoptosis in 
chemoresistant breast cancer159. Triple negative MDA-MB-231 breast cancer showed high 
expression levels of SphK1159. 
 
Previous findings indicate both SphK1 and SphK2 are involved in TNBC progression; 
however, which isozymes plays more significant role in tumor growth needs further 
investigation. Differences in expression levels of SphK1 or SphK2 can change sphingolipid 
levels and cause pro- or anti-cancer behaviors. However, roles of sphingolipid plays in triple 
negative breast cancers are not well studied compared to ER-positive cancers, therefore 
whether S1PRs are involved and which receptors affect tumor progression remains unclear. 
Different breast cancer subtypes respond differently to the sphingolipid pathway. These 
differences can be utilized to determine the prognosis of the disease. Understanding the 
mechanism of S1P involvement in breast cancer would expect to lead to new therapeutic 
strategies.  
 
1.2.6 S1P AND CHEMORESISTANCE 
 
Cancer cells adapt various mechanisms to protect themselves from the harmful effect of 
anti-cancer drugs. As previously mentioned, ceramide–sphingosine–S1P rheostat is an 
important modulator of cell fate with ceramide and sphingosine being apoptotic molecules 
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whereas S1P is considered as anti-apoptotic molecule75. According to the model, adjusting  
this balance between ceramide and S1P can increase or decrease resistance to 
chemotherapy82. Given the significant role sphingolipids have on cell survival, altering the 
metabolism of sphingolipids by overexpressed xenobiotic metabolizing enzymes can increase 
cancer cell resistance to chemotherapy.  
 
Many anticancer drugs increase ceramide accumulation leading to apoptosis and cell 
death160. Apoptosis occurs due to activation of caspases and loss of cytochrome c161, and  
increased degradation of ceramide and inhibited generation is adapted to suppress 
apoptosis162. 
Ceramide/S1P rheostat implication in chemoresistance is correlated to SphK1 
expression. Overexpression of SphK1 alters ceramide/S1P ratio causing more production of 
the oncogenic S1P in Panc-1 cells163. Consequently, Panc-1 cells become more resistant to 
gemcitabine treatment. 
Higher S1P/ceramide ratio is associated with increased resistance to chemotherapy in 
melanoma cells. This is consistent with S1P being anti-apoptotic in tumor cells164. The 
overexpression of SphK1 in melanoma cells favors increased production of S1P, which 
implies decreased ceramide levels. Consequently, the contributions of dysfunctional 
sphingolipids metabolism in drug resistance have been studied in various human cancer cells.  
Dysregulation of sphingolipids metabolism by S1P overproduction inhibited apoptosis in HL-
60 leukemia cell lines by doxorubicin. Furthermore, increased S1P degradation was 
associated with decreased resistance to cisplatin165.  
Multidrug resistance (MDR) in cancer chemotherapy has been associated with 
sphingolipid signaling pathway. S1P regulation of P-gp function was demonstrated in rat 
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brain endothelial cell line RBE4166. SphK1 overexpression in RBE4 cells induced P-gp 
expression suggesting the crucial role S1P plays in the development of the MDR. The effect 
of S1P on P-gp transport activity through S1P1 and S1P3 receptors was determined by 
measuring vinblastine accumulation of inside RBE4 cells. Increased vinblastine efflux was 
attributed to increased P-gp activity mediated by SphK1 overexpression166. Additionally, HL-
60 cell, an acute myeloid leukemia cell, with high expression levels of SphK1 showed 
increased resistance to chemotherapeutic drugs namely, doxorubicin and etopside167. This 
finding provides supporting evidence of S1P implication in MDR in cancer. Inhibition of 
apoptosis induced by anticancer drugs due to SphK1 overexpression in tumor cells led to the 
development of SphK1 inhibitors to overcome chemoresistance. The use of these inhibitors 
demonstrated increased sensitivity to chemotherapeutic drugs by inhibiting S1P synthesis143. 
These findings support the role S1P plays MDR proteins expression subsequently in cancer 
progression and chemoresistance. High S1P receptor expression levels, S1PR1, and S1PR3, 
are associated with resistant to tamoxifen treatment149. 
 
1.2.7 TARGETING S1P PATHWAY IN CANCER THERAPY  
 
As mentioned above, the S1P pathway has been implicated in cancer pathogenesis. 
Strategies for targeting S1P production and function in cancer is promising. Current strategies 
for targeting S1P signaling in cancer focus mainly on modulating S1P receptor signaling 
and/or SphK inhibitors. Blocking S1P production in tumor cells and or altering its level is the 
basic concept of these strategies. The combination of chemotherapeutic agents with 
sphingolipid pathway modulators to achieve a synergistic effect and more selective targeting 
is being investigated. 
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Modulating S1P receptor signaling by FTY720, an S1P analog which binds to four of 
five S1P receptors (S1P1, S1P3, S1P4, S1P5), was found to induces apoptosis in-vitro in 
several cancer cell lines168. Furthermore, FTY720 stopped tumor growth and metastasis in a 
mouse model of breast cancer. Cancer cells showed high susceptibility to treatment with 
FTY720168. Although FTY720 is a S1P receptor agonist, it was found to reduce angiogenesis 
and vascularization in tumors suggesting a new approach for treatment169. 
Another approach for targeting S1P is depletion of extracellular S1P by S1P specific 
antibodies. LT1009 reduced proliferation and increased apoptosis in tumor growth and 
metastasis in breast and ovarian cancers170. This approach was based upon the abundant 
levels of S1P in the extracellular environment that is above the Kd of S1P receptors and its 
reported effect on proliferation and metastasis. 
SphK1 overexpression in a variety of solid tumors makes it a rational target for 
selective treatment. In general, the main target for these inhibitors is to block or decrease the 
production of S1P and increase the concentration of ceramide. Inhibition of SphK1 in-vitro 
and its effect on S1P production has been extensively studied using dimethyl sphingosine, an 
N-methylated metabolite of sphingosine. The inhibition was observed on the growth and 
metastasis of melanoma cancer cells102. Another SphK inhibitor, SK1-I (BML-248), induced 
apoptosis in leukemia cells171.  
 
1.2.7.1 S1P AS AN ANTICANCER AGENT   
 
The production a synergistic effect using drug combination is a common strategy for 
cancer therapy. The aim of combination therapy is to produce maximum kill and avoid drug 
resistance. In an attempt to find more useful drug combination for treating different tumors, a 
few in- vitro studies reported the beneficial use of S1P in combination with various clinically 
available chemotherapeutic drugs. Dr. Yang’s research group reported that exogenously 
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administered S1P exhibited synergistic effects with chemotherapy drugs doxorubicin and 
docetaxel in human breast cancer MCF7 and MDA-MB-361 cells92 172. 
 Their research utilized S1P in combination based on the fact that S1P itself can 
produce cell death. This combination maybe the next era of cancer treatment. 
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2. OBJECTIVES AND HYPOTHESIS  
 
2.1 OBJECTIVES: 
1. Understanding whether S1P can selectively induce apoptosis in human TNBC/BLBC 
cell lines at low µM concentration range. 
2. Investigating whether S1P can exert a synergistic and/or additive effect with 
chemotherapeutic agents doxorubicin and docetaxel towards TNBC/BLBC. 
 
 
 
2.2 HYPOTHESES: 
 
We propose sphingosine-1-Phosphate (S1P) as a target for breast cancer treatment. 
1. S1P induces apoptosis and necrosis in breast cancer cells at a concentration above 
0.1 µM. 
2. S1P sensitizes human breast cancer cell to chemotherapeutic agents. 
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3. MATERIALS AND METHODS 
     3.1MATERIALS  
    3.1.1 CHEMICALS AND CELLS 
 
Sphingosine-1-phospahate (S9666- 1 mg), docetaxel (01885- 5 mg), and doxorubicin 
(D1515- 10 mg) were purchased from Sigma-Aldrich (Oakville, ON, Canada). Triple 
negative/Basal-like cell lines were purchased from American Type Culture Collection 
(ATCC) (Manassas, VA, USA). Nine triple-negative breast tumor cell lines share a basal-like 
morphology (HCC1599, HCC1937, HCC1143, MDA-MB-468, HCC38, HCC70, HCC1806,  
HCC1187, DU4475). 
Table 1: Summary of Triple Negative Breast Cancer Panel 1 (ATCC® No. TCP-1001™)   
illustrating cell line grade, histology, and mutation data. 
Cell Line Grade Histology Mutant Gene 
HCC1599 TNM stage IIIA, grade 3 Primary ductal carcinoma TP53,KDM6A 
HCC1937 TNM stage IIB, grade 3 Primary ductal carcinoma TP53, BRCA2 
HCC1143 TNM stage IIA, grade 3 Primary ductal carcinoma TP53,BRCA1 
MDA-MB-468 NA Adenocarcinoma PTEN,TP53,SMAD4,RB1 
HCC38 TNM stage IIB, grade 3 Primary ductal carcinoma TP53,CDKN2A 
HCC70 TNM stage IIIA, grade 3 Primary ductal carcinoma PTEN,TP53 
HCC1806 TNM stage IIB, grade 2 squamous cell carcinoma CDKN2A,KDM6A,STK11,TP53 
HCC1187 TNM stage IIA, grade 3 Primary ductal carcinoma TP53 
DU4475 NA Carcinoma APC, BRAF,MAP2K4, RB1 
Abbreviations: TP53: tumor suppressor p53, KDM6A: Lysine (K)-Specific Demethylase 6, BRCA1: Breast 
Cancer 1 Tumor Suppressor, BRCA2: Breast Cancer 2 Tumor Suppressor, PTEN: Phosphatase and tensin 
homolog, SMAD4: SMAD Family Member 4, RB1: Retinoblastoma-Associated Protein, CDKN2A: Cyclin-
Dependent Kinase Inhibitor 2A, STK11: Serine/Threonine Kinase 11, MAP2K4: Mitogen-Activated Protein 
Kinase 4. BRAF: B-Raf Proto-Oncogene, Serine/Threonine Kinase, APC: Adenomatosis Polyposis Coli Tumor 
Suppressor 
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          Penicillin/streptomycin solution was purchased from Sigma Life Science (Kansas City, 
MO, USA). Leibovitz’s L-15 medium was purchased from Life Technology (Carlsbad, CA, 
USA). RPMI-1640 medium was purchased from Hyclone (Logan, Utah), and Fetal Bovine 
Serum (FBS) was purchased from Sigma life Science. 0.25 % Trypsin-EDTA was purchased 
from Sigma Life Science. CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay, 
Cell CytoTox96®Non-Radioactive Cytotoxicity Assay System, and CellTox™ Green 
Cytotoxicity Assay were purchased from Promega (Madison, WI, USA). Annexin V-FITC 
Apoptosis Detection Kit was used to detect apoptosis. Kits were purchased from Biotool, 
Houston, TX. 96-Well Optical-Bottom Plates, 96 Well Plate Polystyrene, and 6 well plates 
were purchased from Thermo Scientific. Corning® 75cm² straight Neck Cell Culture Flask 
with Vent Cap (Corning, NY) and Thermo 25 cm2 (Waltham, Massachusetts) were used for 
cell culture.  
 
3.1.2 COMPOUNDS AND BUFFERS PREPARATION 
 
Stock solutions were prepared for S1P dissolved in methanol at 2.64 mM, docetaxel 
in ethanol at 2 mg/mL, doxorubicin in water at 1 mM, 1x PBS buffer (pH 7.4) was prepared 
by dissolving the following chemicals in 800 mL distilled water: 8 g NaCl, 0.2 g KCl, 1.44 g 
of Na2HPO4, and 0.24 g of KH2PO4. The pH was adjusted to 7.4 by adding HCl and then the 
volume was adjusted to 1L. The final PBS solution was sterilized by autoclaving. 4% 
paraformaldehyde was prepared by dissolving 4g  paraformaldehyde powder in 100 mL of 1x 
PBS, and the final solution was heated at 37°C water bath for 1-2 hours. 
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3.2 METHODS 
3.2.1 CELL CULTURE 
 All breast cancer cell lines except HCC1599 were cultured in T-75 culture flasks 
according to ATCC protocol. The medium was supplemented with 10% FBS and 1% 
penicillin/streptomycin. HCC1599 breast cancer cell line was cultured in T-25. RPMI-1640 
medium was used to culture all cell lines except MDA-MB-468, which was cultured using 
Leibovitz's L-15 medium. All cell lines were incubated under a humidified 5% CO2 
atmosphere at 37°C except cell line MDA-MB-468 was incubated under 0% CO2 atmosphere 
at 37°C. Cell culture media were changed 2-3 times a week. Cells were sub-cultured by using 
0.25% trypsin-EDTA solution after they reached 70 % confluence. 
3.2.2 CYTOTOXICITY STUDIES 
 
Cells for each were plated in 96-well plates at different density. The number of cells 
varied from each cell line. The plated cell number was 10000 cells/well for HCC1599, 15000 
cells/well for HCC1937 15000/well, 10000 cells/ well for HCC1143, 7000 cells/well for 
MDA-MB-468, 7000 cell/well for HCC38, 7000 cell/well for HCC70, 7000cell/well, for 
HCC1806, 10000 cells/well for HCC1187, 10000 cells /well for DU4475. Cell number for 
each cell line was obtained for pilot studies. The cells in suspension were mixed with 20µl of 
CellTox™ Green dye and plated. All cells were incubated for 24 hours before  being treated 
with S1P concentrations ranging from 20µM to 0.1µM. Cells were treated with S1P and left 
for an hour before applying the chemotherapeutic drug. Maximum LDH release buffer was 
used as positive control. Solvent only cell were used as negative control S1P cytotoxicity was 
measured at exposure time of 24h, 48h and & 72h using CellTox™ Green Cytotoxicity Assay 
kit according to manufacturer’s instructions. The kit measures changes in membrane integrity 
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that occur as a result of cell death by staining DNA molecules of the dead cells. Fluorescence 
was determined at 485–500 nm Excitation/520–530nm Emission using a BioteK plate reader. 
Positive controls (Lysis buffer) and negative controls (solvents) were used and % cytotoxicity 
was determined using the following formula:  
 
 
 
The data were plotted as % cytotoxicity vs. S1P concentration. GraphPad Prism 
software was used to evaluate the data. The results were plotted as concentration vs % 
cytotoxicity at each time point. 
  
3.2.3 CELL PROLIFERATION ASSAY 
 
96-well tissue culture plates were seeded with different cell densities and incubated at 
37ºC, and 5% CO2 except for cell line MDA-MB-468 which was incubated at 0% CO2 until 
they reached 70% confluence. Cells were then treated with S1P (concentration range: 0.1- 20 
μM) and incubated for 72 h. Methanol treated cells were used as negative control. The assay 
was carried out by using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation 
Assay kit, as per manufacturer’s protocol. Plates were measured using a BioteK plate reader 
to measure the absorbance at 490 nm.  
 
The number of living cells was measured by the quantifying formazan as a result of 
the MTS conversion by dehydrogenase enzyme in metabolically active cells (i.e. 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)). Data 
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were plotted as % increase of cell proliferation compared to the control vs. S1P concentration 
and the results were analyzed using GraphPad Prism software. The final data were plotted as 
% increase of cell proliferation vs. time in hours. 
3.2.4 APOPTOSIS STUDIES 
 
Annexin V-FITC kits were used for apoptosis detection. Annexin V-FITC kit detects 
the externalization of phosphatidylserine in apoptotic cells. Annexin V conjugated to green-
fluorescent fluorescein isothiocyanate (FITC) dye binds to phosphatidylserine sites on the 
member of apoptotic cells. Propidium iodide (PI) binds to necrotic cells. Treatment of cell 
with Annexin and PI dyes stains dead cell but not live cells. Apoptotic cells give green 
fluorescence, and necrotic cells show green and red fluorescence. 
Cells were seeded in six-well plates at a density of 10000 cells/well with two mL 
growth medium. After 24 h, the medium was changed to the adherent cell medium. 
Moreover, cells were treated with S1P alone at concentration obtained from the cytotoxicity 
studies for each cell line and methanol was used as a negative control. Nonadherent cells 
were treated after 4 h of plating. After 72 hr treatment, the medium and cells were collected 
in 15 mL conical tubes. 500-μL trypsin was then added to each well and after 2 min, the 
trypsin was neutralized by adding 200 μL of cell culture media containing FBS buffer. The 
cells were then collected and added to the previously collected medium. Collected cells were 
then centrifuged at 300g for 5 min at room temperature. Then, the supernatant was removed, 
and the plate was washed with PBS buffer. Cells were centrifuged again for 5 minutes. The 
supernatant was removed, and cells were suspended in 100µL buffer. 5 μL Annexin V -FITC 
and 5 μL PI Staining Solution were added to each 100 μL of cell suspension. Cells were then 
incubated for 15 min at room temperature. After incubation, 400 μL of 1 × binding buffer 
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was added to each tube and then transferred to flow cytometry tubes and kept on ice. 
Measuring the fluorescence emission was done using FACSCalibur™. 
ZOE™ Fluorescent Cell Imager was used to capture an image of wells treated with S1P and 
non-treated wells. Images were taken after 72 h of treatment for both treated and non-treated 
cells. 
3.2.5 CHEMOTHERAPY COMBINATION STUDIES 
 
All nine cell lines were seeded in 96 well plates with varying density as described in 
the cytotoxicity studies. Cells were treated with different concentrations of chemotherapeutic 
drugs alone or in combination with S1P. Three different concentrations of S1P 10µM, 
1µM,and 0.1µM. The two chemotherapeutic agents were selected to perform this part are 
docetaxel (concentration 5-40 µM) and doxorubicin (concentration 2.5-20 µM). After 
treatments had been administered, cell lines were incubated for 72 h at 37°C and 5% CO2 
except for cell line MDA-MB-468, which was incubated in 0% CO2. Measurement of cell 
death was done using the CytoTox 96® Non-Radioactive Cytotoxicity Assay kit. This test is a 
colorimetric test that measures the conversion of a tetrazolium salt into formazan. This 
process is achieved by lactate dehydrogenase enzyme that is released upon cell lysis. The 
intensity of the color is proportional to the number of dead cells. 
The BioteK plate reader was used to measure the absorbance at 490nm. The percent 
of cell death was determined by using the following formula: 
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The data obtained were grouped based on the type of treatment (Chemotherapeutic 
agent plus S1P and Chemotherapeutic agent alone). Each treatment was grouped into four 
group representing the four concentration of the chemotherapeutic drug used.  
 
3.2.6 STATISTICAL ANALYSIS 
 
GraphPad Prism software was for data analysis. The mean ± SD for each assay was 
calculated from three independent experiments with three replicate per each independent 
experiment. Comparison between the effects of the anti-cancer drugs alone or in combination 
with S1P was performed using the t-test. P-value <0.05 was considered significant. 
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4. RESULTS 
       4.1 CYTOTOXICITY STUDIES 
 
The cytotoxic effect of S1P was evaluated for up to 72h. Each cell line was evaluated 
for exposure to a wide range of S1P concentrations (0.125-20µM) at 24, 48, and &72h. The 
response of the nine cell lines towards the S1P treatment of different concentrations was 
summarized in Table2 and Figure 3. S1P showed a time-dependent effect in the 
TNBC/BLBC cell lines. 
In general, prolonged exposure to lower concentrations of S1P caused higher 
cytotoxicity compared to higher concentrations and highest toxicity was achieved after 72 hr 
of exposure. 
 HCC1937 (CRL2336) showed highest cytotoxicity among the nine cell lines after 
prolonged exposure to lower concentrations of S1P. Highest toxicity was achieved at 72 h 
exposure. Highest cell death of about 76 % achieved at 0.1 µM while the number of cell 
death decreases as S1P concentration was increased. S1P did not cause any significant 
increases in cell death in HCC1806 (CRL2335). Maximum cell death reported about 8% after 
prolonged treatment for 72h. The concentration that produced maximum cell death varied in 
cell lines. HCC1143 (CRL2321) showed increased cell death at 10µM. HCC70 (CRL2315) 
showed maximum cell death at 5µM.  
 
 
.  
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Figure  3 : Percent cytotoxicity (mean±SD) of nine TNBC/BLBC cell lines following 
treatment with different concentrations of S1P for 24, 48 and 72 hr. Cells treated with 
complete growth medium and solvents were used as a control. The mean± SD was calculated 
from three independent experiments, *=P<0.05. 
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4.2 CELL PROLIFERATION STUDIES: 
 
Cell proliferation was assessed using CellTiter 96 AQueous proliferation assay. The 
absorbance of MTS product, the metabolic conversion of a tetrazolium compound MTS to a 
colored product by live cell was measured. S1P showed a bell-shaped dose response curve on 
human TNBC/BLBC cell lines. All cell lines were exposed to different concentrations of S1P 
for 72 h.  
HCC1599, HCC1937, HCC1143, MDA-MB-468, HCC38, HCC70, HCC1187, and 
DU4475 demonsterated a proliferation response while in cell line HCC1806, no response was 
observed. Maximal proliferation was achieved at 0.3 μM and 5 μM in responsive cell lines. 
Prolonged cell exposure to S1P concentrations of 10µM or higher inhibited cell proliferation. 
No inhibition of cell growth was observed in HCC38 cell line. HCC1187 cell line 
showed maximum proliferation at 2.5µM of about 12%. HCC1599 cell line was observed to 
have a higher percent of cell proliferation around 1% at 2.5µM. S1P did not produce any 
effect on cell proliferation for the HCC1806 cell line. HCC1937 cell line showed cell 
proliferation of about 17% at 2.5 μM. DU4475 cell line had plateaued proliferation of around 
14% at 0.3-5µM. MDA-MB-468 also showed a plateau of proliferation around 14% at same 
concentrations. HCC1143 was observed to have a maximum proliferation of 16% at 2.5 µM. 
HCC70 cells reached high proliferation level of 7% at a concentration around 2.5µM. At 
higher S1P concentration the proliferation decreased. 
In summary, S1P induced marginal proliferation in TNBC/BLBC cell lines with 
maximal effect of 16% increase over control at 2.5µN S1P towards HCC1599 cells. 
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Figure  4 : Percent increase of cellular proliferation (mean± SD) compared to control in 
TNBC/BLBC cell lines after being treated with different concentrations of S1P. Cells treated 
with the complete growth medium and solvents were used as a control. The mean±SD was 
calculated from three independent experiments.  
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4.3 APOPTOSIS STUDIES 
 
Based on the results from the previous sections, I tried to assess the inhibitory effect 
of S1P and determine whether S1P induces apoptosis using the Annexin V assay. S1P 
inhibited proliferation in all nine cell lines after 72 hr. Treating cells with S1P caused the cell 
to detach, shrink and round as shown in the Figure 7. 
Cell line HCC1599 showed the highest response to S1P treatment with inhibition of 
about 55 percent and the results were statistically significant compared to untreated cells (p-
value< 0.05). HCC038 showed inhibition of growth ranging from 20- 30 % and the 
difference between the treated cell and untreated cell was significant (p –value < 0.05). In 
HCC1806, S1P induced apoptosis at about 20%. However, this inhibition was not significant 
compared to non-treated cells. As reported in cytotoxicity part, this cell line was least 
responsive to S1P treatment. 
 
Table 2: Summary of cytotoxicity, proliferation, and apoptosis tests in TNBC/BLBC cell 
lines 
Cell Line Cytotoxicity Proliferation Apoptosis 
HCC1599-CRL2331 64% (0.1µM) 17%  (2.5µM) 56% 
HCC1937-CRL2336 70% (1.25µM) 13%  (5 µM) 33% 
HCC1143-CRL2321 31% (10µM) 15% (2.5µM) 20% 
MDA-MB-468 24% (0.1 µM) 16% (0.3µM) 36% 
HCC38-CRL2314 21% (0.3µM) 2%  (0.1µM) 33% 
HCC70-CRL2315 37% (5µM) 7%  (2.5µM) 27% 
HCC1806-CRL2335 8% 2%  30% 
HCC1187-CRL2322 28% (2.5µM) 12% (1.25µM) 19% 
DU4475-HTB123 40% (0.3µM) 14% (5µM) 28% 
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Figure  5 : Percent apoptotic cell death using flow cytometry method comprising non-treated 
cell with S1P treated cell after 72 hr. Cells treated with complete growth medium and solvent 
was sued as control. Annexin V apoptotic assay was used as described in methods section the 
percent of cell death was calculated from three independent experiments N = 3, *=P<0.05. 
***=P<0.001. p-values are shown under each figure. 
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        Figure6: Flow cytometry analysis of the nine TNBC/BLBC cell lines after being treated with 
different concentration of S1P compared to non-treated cells after 72 hrs. Cells treated with complete 
growth medium and solvent was used as control. Annexin V apoptotic assay was used as described in 
methods section the percent of cell death was calculated from three independent experiments N = 3 
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Figure 7: Nine TNBC/BLBC cell lines after 72 hr  treatment with different S1P 
concentration compared to untreated cells. S1P caused the cell to shrink, round and detached. 
ZOETM Fluorescent cell image from Bio-Rad was used to take these images. Cells treated 
with complete growth medium and solvent was used as control.  
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4.4 CHEMOTHERAPY COMBINATION STUDIES 
 
The combinations of the chemotherapeutic agent docetaxel (DOC) and doxorubicin 
(DOX) with S1P were evaluated for 72 hr in the nine cell lines. 
Each cell line responds differently to treatments. Combination studies of DOX with 
S1P in HCC1599, showed a reduction in cell death compared to DOX treatment alone as 
shown in Figure 8 (p-value < 0.0001). Maximum cell death achieved by DOX alone was 
around 45% at a concentration of 20 µM while when combined with S1P the cell death 
dropped to around 25 %. The impact of S1P co-treatment with DOC in the same cell line did 
not show any difference from DOC treatment alone. Although the combination showed 
higher cell death at 40µM and 10µM DOC, the difference was not statistically significant (p-
value > 0.05). In HCC1937, S1P co-treatment with DOX resulted in a significant decrease in 
the percentage of cell death at concentrations, 20, 10 and 5µM (P-value<0.05) but not at 
2.5µM. S1P co-treatment with DOC showed no significant difference in the percentage of 
cell death at any concentration. The DOC treatment showed higher cell death compared to 
DOX treatment. HCC1806 cell line showed no significant difference between the 
chemotherapy alone as compared with the combination for both DOC and DOX. However, 
DOX cytotoxicity results show that this cell line is more responsive to DOX than DOC (P-
value < 0.05) is. HCC1187 cell line results show a significant decrease in the percentage of 
cell death for both DOX and DOC when co-administered with S1P. DOX combination 
showed significant reduction in the cytotoxic effect at concentration of 20, 10, 5µM (p value< 
0.05) and no significant difference at 2.5µM. DOC combination showed significant reduction 
at 40, 20, 10µM but no significant reduction at 5µM. The results also show that this cell line 
is more responsive to DOC than DOX (p value<0.05). HCC1143 combination of DOX with 
S1P results showed no significant advantage of the combination over the chemotherapy 
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treatment alone for all concentrations (p-value<0.05). DOC combination showed more 
reduction in the percentage of cell death at high DOC concentration (40 and 20 µM, p-
value<0.05). However, at low DOC concentrations there was no significant difference. No 
significant difference was observed between the DOC and DOX treatments. 
MDA-MB-468 co-administration of S1P with DOX resulted in a more significant 
reduction in the percentage of cell death and the difference was more pronounced at higher 
concentration (p-value<0.0001). The combination of S1P with DOC showed no significant 
result over DOC treatment alone. MDA-MB-468 cell line shows a more significant response 
to DOX over DOC (p-value <0.05). HCC38,  ATCC CRL-2314  S1P combination with DOX 
showed an increase in  the number of dead cells at high concentrations. However, this 
increase was not significant (p-value> 0.05) and at a lower concentration the combination 
showed a reduction in the number of dead cells ( P value< 0.05). DOC combination showed 
no advantage in increasing percentage of cell death. The difference in response to DOX 
treatment and DOC was not significant in this cell line. The combination of S1P and DOX in 
HCC70 did not show an increase in number of dead cells in this cell line. The combination of 
S1P with DOC showed a significant reduction in the number of the dead cells at higher 
concentration (P-value <0.05). DOC treatment produced a cell death of about 77 % while the 
DOX treatment achieved a maximum of 22 %. For DU4475, S1P-DOX combination showed 
significant reduction in the number of dead cells at higher concertation while at lower 
concentration the number of dead cells was not significantly different from DOX treatment 
alone. DOC combination with S1P did not show any significant difference from DOC 
treatment alone. Both DOX and DOC produced approximately the same percentage of dead 
cells in DU4475 cell line. 
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Figure 8: S1P combination with DOX /DOC compared to DOX/DOC alone after 72 hr. 
incubation in TNBC/BLBC cell lines. Four different concentrations of the chemotherapeutic 
drug used with three different concentrations of S1P (10,0.1µM and concentration that 
produced maximum death in cytotoxicity studies). CytoTox 96® Non-Radioactive 
Cytotoxicity assay was performed as described in the method section. Cells treated with the 
complete growth media and the solvent were used as the control. Results are shown as mean 
± SD. The mean ± SD was calculated from three independent experiments N = 3, *=P<0.05. 
***=P<0.001 
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5. DISCUSSION  
 
Developing novel agents and tailoring regimens to an individual patient is the main 
goal of cancer treatment. A selection of appropriate treatments for breast cancer patients 
requires a better understanding of different subtypes of tumors. TNBCs have poorer 
prognosis than other subtypes of breast cancer, and risk of recurrence is high. Lack of 
selectivity of clinically available chemotherapeutic drugs comprises one of the major 
challenges in cancer treatment. Therefore, research is now being focused to find more 
selective treatment with fewer side effects on normal cells.  
Various intracellular and extracellular biological processes are controlled by S1P. 
Targeting sphingolipid pathways is being used as therapeutic strategies for the treatment of 
cancer. S1P is normally reported to increase cell proliferation, migration and angiogenesis in 
cancer. However, several studies reported the involvement S1P in cell death92 173.  
 
5.1 SPHINGOSINE-1-PHOSPHATE DUAL EFFECT IN TRIPLE 
NEGATIVE /BASAL-LIKE BREAST CANCER  
 
  The focus of this study is to examine the cytotoxicity of the bioactive lipid, S1P, in 
TNBC/BLBC cell lines. All nine cell lines are characterized by lacking expression of ER, PR 
and HER2/neu receptors, and they share basal-like morphology. The present study was 
undertaken to determine how cancer cells that lack the expression of ER, PR, HER/neu would 
respond to S1P treatment. 
Evaluation of S1P toxicity against TNBC/BLBC cells was done in-vitro. For the 
TNBC/BLBC cell lines, cells do not die immediately after treatment with S1P. For most of 
the cell lines, significant death occurs after 48 to 72h (Figure 3). Our data demonstrated 
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greater sensitivity to S1P after 72h treatment for the TNBC/BLBC cell lines. S1P gave a 
consistent response in all cell lines except HCC1806 cell line, which was less responsive to 
S1P treatment. This study is the first to show that S1P promotes cell death in TNBC/BLBC 
cells in a narrow window of concentrations. There is no previous report on the effect of 
exogenously administered S1P on TNBC/BLBC. Our previous studies also reported the effect 
of S1P on the proliferation of MCF7, MDA-MB-361, and MDA-MB 231 cells. These studies 
showed that S1P induced cell death at higher concentrations92.            
In the proliferation studies (Figure. 4), it was found that treatment of these breast 
cancer cells with various concentrations of S1P 0.1-20 μM for 72 h inhibited proliferation at 
high concentrations and showed more proliferative effect at lower concentrations. 
Cytotoxicity and proliferation results provide supporting evidence that the effect of 
S1P is concentration-related89, as well as the dual action of S1P76. These results also suggest 
that S1P has intracellular and extracellular targets responsible for producing these actions. 
Different physiological processes are regulated by S1P via its five G-protein coupled 
receptors174, and different types of cells have different expression levels of S1PRs175. 
Although the intracellular action of S1P is not yet identified, it seems from the data obtained 
that intracellular function is independent of the cell surface receptor function. Several reports 
showed that S1P induced cell survival and proliferation by extracellular mechanisms176 177. 
The result obtained from our proliferation studies are in line with previous research that cell 
surface S1P receptors promote cell proliferation and survival. However, cytotoxicity studies 
suggest that external S1P may be transported into the cells. Response at lower concentrations 
rather than high concentrations can be explained as S1PRs are saturated at higher 
concentration of S1P and are only activated at nanomolar concentration178. The inhibitory 
effects of S1P are observed at micromolar concentrations, whereas G protein activation is 
observed at nanomolar concentrations as reported by Davaille178. Inhibition of cell migration 
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by exogenous administration of S1P was reported to be receptor independent and attributed to 
intracellular mediated mechanism168.  
S1P was found to induce apoptosis in human hepatoma cells (Hep3B)  in dose-
dependent manner179. Another study reported S1P induction of apoptosis in hippocampal 
neurons180. These reports indicate that S1P has anti-proliferative action, yet the exact 
mechanism is still unknown. 
These results may be explained as follows, first depending on the cell type, different 
cells respond differently via intracellular or receptor-mediated activities. Second, the 
intracellular action may be affected by different concentrations of S1P, as the exogenously 
administered S1P has a higher concentration on the outside, whereas the intracellular effects 
may require less concentration of S1P. Another explanation could be that S1P administered 
can induce the generation of intracellular S1P, which then can interact with the intracellular 
target. 
 
In summary, this study shows that S1P has a dual effect on TNBC/BLBC, and the 
effect is concentration-dependent. Proliferation studies showed that at low concentrations 
S1P marginally stimulated survival pathway and at higher concentration it exhibited an anti-
proliferative effect (Figure 4). Since we have no information about the degradation of 
exogenously administered S1P and no available information about the expression of S1PRs in 
these cell lines, and S1PR2 responsible for the  anti-proliferative effect S1P109, I suggest that 
S1P interact with S1PR2 and producing this effect. 
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5.2 SPHINGOSINE-1-PHOSPHATE INDUCESES APOPTOSIS IN 
TRIPLE NEGATIVE/BASAL-LIKE CELL LINES 
 
In this part, I aimed to determine whether the inhibitory effect of S1P is due to 
apoptosis. The results obtained from this part indicated that S1P significantly reduced cell 
viability. These results are in line with previous with previous reports 92 128 129 180. 
This is the first study to report that S1P induces apoptosis in TBNC/BLBC cells. The 
exact mechanism is still unknown. However, from previous studies done on different cell 
lines it was shown that S1P inhibitory action is independent of the S1PR. These results 
suggest that the proliferation inhibitory action is achieved by intracellular targets. Previous 
studies pointed that the inhibitory action of S1P is not related to its cell surface receptor by 
measuring the intracellular concentration of S1P. The intracellular concentration was reported 
to be higher than in control cells180. Shin et al. studied the effect of exogenous S1P in 
melanoma cells. In their experiment, they used Dihydrosphingosine, an S1P analog which 
activates S1PR, which did not produce the same action of exogenous S1P176 indicating that 
the apoptotic effect of S1P is not mediated by cell surface receptors. They reported that the 
apoptotic effect of exogenous S1P was mediated by caspase-3 activation128. Moreover, the 
apoptotic effect of S1P was not related to metabolic conversion to ceramide as reported by 
Davaille et al.129. In all these previous studies, each cell line responded to different S1P 
concentrations indicating that concentration is cell line specific and S1P concentrations 
determine its effect. 
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5.3 SPHINGOSINE-1-PHOSPAHTE AND CHEMOTHERAPY 
COMBINATION 
 
One of the main objectives of this project is to identify new drug combinations that 
synergistically reduce the viability of tumor cells. To assess whether the combination of S1P 
and chemotherapeutic agents doxorubicin and docetaxel potentiate cytotoxic effects in the 
nine cell lines, cell were treated with either docetaxel, doxorubicin alone or with their 
combination with S1P  for 72 h. Cytotoxicity studies of S1P alone revealed that S1P has a 
modest effect on cell death. As mentioned above, chemotherapy remains the mainstay of 
TNBCs due to lack of specific targets. However, the recurrence rate is still high. Neoadjuvant 
anthracycline, Taxanes are mostly commonly used drugs in the treatment of TNBCs181. 
Doxorubicin is an anthracycline antibiotic that is used for the treatment of different types of 
tumors. The major mechanism of Doxorubicin action is intercalation into DNA and through 
the generation of free radicals182. Briefly, Doxorubicin enters the nucleus and interact act 
with the DNA resulting in DNA damage.  
Docetaxel belongs to taxanes drug class that acts by stabilizing microtubule 
assembly183. Docetaxel is an anti-microtubules agent that prevents depolymerization of 
microtubules promoting apoptosis in tumor cells 184. Docetaxel has several mechanisms of 
action that is not exclusive to mitosis inhibition. Apoptosis induction by docetaxel is a very 
complex process involving several transduction pathways. 
In the previous experiments, I have identified that S1P causes marked reduction of the 
viability of apoptosis in TNBC/BLBC cell lines (figure 8). However, the results obtained 
from combination studies showed no advantage over the chemotherapy alone. A substantial 
reduction in a number of dead cells was observed in different cell lines. These results raise 
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the conundrum of how S1P alone caused cell death, whereas in combination with docetaxel 
or doxorubicin the percentage of cell death in some cell lines was decreased.  
 
The neutralizing responses and reductive responses observed in this combination can 
attributed to pharmacokinetic and/or pharmacodynamics interactions. Pharmacokinetically, 
the interaction may be due to decreased permeation and transport of one or both components, 
increased metabolism and increased the efflux of one or both components of the combination. 
Tumor microenvironment can influence the action of the chemotherapeutic agent. With the 
intracellular pH is higher than the extracellular pH, the diffusion of drug into the cell is 
influenced by the acidic pH of the extracellular environment. Protonation of weak acid drugs 
such as doxorubicin decreases its uptake185 186. The decreased effect of the combination can 
be due to reduced S1P or the chemotherapeutic agents transport into the cell. Reduction of 
paracellular permeability due to aggregation, inhibited uptake of both S1P and the drug, or 
decreased transport of both S1P and its partner drug can be a potential reason for the 
deacreased effect of the combination. Aggregation reduces the permeability of S1P and or 
chemotherapy thus results in a reduction of cell death compared with chemotherapy alone. 
Competitive inhibition of transporter or target site is also a possible explanation for 
the observed results. Since the exact mechanism of cellular uptake of docetaxel, doxorubicin 
and S1P is unknown, a reasonable explanation that pharmacokinetic antagonism at the 
cellular uptake level may have reduced the uptake of S1P and or the chemotherapeutic agent.  
Since the mechanism of S1P uptake into the cell in not well known and the 
chemotherapeutic drug, doxorubicin and docetaxel uptake into the cell is not fully 
understood, an assumption is that S1P and chemotherapeutic drug share the same drug 
transporter uptake mechanism. Both drugs in the combination compete for the same 
mechanism. Assuming that some of the S1P does not enter the cell when combined with these 
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drugs, more S1P is available in the extracellular environment and, therefore, producing the 
opposite action. FTY720, the S1P analog has been shown to inhibit ceramide synthase and 
S1P lyase upon binding to extracellular receptors187. Extrapolating these effect on 
extracellular S1P, the reduction of the combination can be strongly attributed to these actions. 
Reduction in the action of the combination can also be explained by increased 
metabolism. An assumption that one of the components of the combination increases the 
metabolism of the other. Supporting this assumption, doxorubicin was also reported to 
increase the production and secretion of S1P by increasing SphK1 expression  188. Moreover, 
SphK1 expression was reported to be upregulated in TNBC155. Doxorubicin was also 
reported to induce expression of SphK1 after 24 treatment in U937 cells 165. Doxorubicin was 
also shown to increase S1P secretion through ABCC1 transporter188. Nuclear S1P is likely to 
be involved in cell arrest189 while extracellular S1P was reported by several studies to 
enhance cell proliferation190. In this regard, rational explanation for the antagonism that the 
combination prevented the administered S1P from entering the cell, hence, interacting with 
cell surface receptor and promoting cell proliferation rather than causing apoptosis. 
S1P hydroxylase1 (SPP1), an enzyme that terminates the action of S1P 191, modulates 
intracellular levels of S1P and thus alters the intracellular ceramide levels. Doxorubicin was 
shown to up-regulate expression of SPP1 in a time-dependent manner192. The same study 
reported that SPP1 downregulation enhanced the apoptotic effect of doxorubicin. Based on 
these result, I assume that doxorubicin enhanced the expression of SSP1 in these cell lines 
causing rapid degradation of S1P. 
The reduction in number of dead cells in the combination can be due to drug efflux 
from the cell. Expression of ABCC1 transporter in ER- breast cancer is associated with poor 
prognosis 193. Resistance to Doxorubicin treatment involves drug transporters. ABCB1, ATP-
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dependent drug pump, acts as drug efflux pump194. Other transporters involved in 
doxorubicin resistance such as ABCC1 (MRP1) ABCC2, ABCC3, ABCG2, and RALBP1195. 
Efflux of doxorubicin from cells has been linked to overexpression of these transporters. S1P 
is also a substrate for ABCC1, ABCA1, and ABCG2 (also known as breast cancer resistance 
protein; BCRP)109. ABCC1, ABCC11, and ABCG2 were found to be highly expressed in 
basal-like breast cancer158 contributing to their aggressive nature and resistant to treatment. 
Docetaxel efflux is influenced by overexpression of ABCB4 and ABCC1, ABCG2183.  
 No information is available yet about the overexpression of the other transporters in 
the nine cell lines. However, assuming that they are overexpressed in TNBC/BLBC cell lines 
that demonstrated less response to chemotherapy alone. The overexpression of these 
transporters may be a strong reason for their responsiveness to treatment. Specific inhibitors 
of ABC transporters may be used to investigate the effect of these transporters in efflux the 
combination one of them or both. 
The results from combination studies can be attributed to the interference of one of 
the components of the combination with the target of the partner drug. One example of 
combination antagonism is that one of the drugs target the related pathway of the other drug 
in the combination, thus reducing or abolishing the action of the partner drug. Spiegel et al. 
reported that doxorubicin decreased the expression of SphK2125. Previous studies have 
reported that overexpression of SphK2 leads to cell death122,126. However, the exact 
mechanism of this process is still unknown. Assuming that SphK2 is the target of 
exogenously administered S1P when given in combination with doxorubicin or docetaxel, 
S1P does not reach its target in sufficient concertation to produce its action. This could be a 
reason the exogenously administered S1P does not interact with its intracellular target.  
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S1P may cause alterations of targets involved in apoptosis that are necessary for 
doxorubicin to produce its effect. Doxorubicin cytotoxicity is achieved by interchelation with 
DNA and inhibition of Topoisomerase II (TOP2A). Reduced cytotoxicity of doxorubicin in 
TNBC is strongly associated with TOP2A mutation196. Therefore, cell lines that show less 
response to doxorubicin treatment alone may have TOP2A mutation. Class III beta-tubulin, a 
protein that make up the microtubules has been associated with increased resistance to 
Taxanes68. MD-MBA-468 was the least responsive to docetaxel treatment alone. No available 
information about the expression of beta-tubulin in these cell lines. However, overexpression 
was reported in different tumors 68. 
Genetic interaction can influence response to therapy, and hence any disruption in the 
form of genetic variation (SNPs, Insertion-deletion and copy number variation) will influence 
how different cells will respond to different treatments. Therefore, examining the changes 
due to genetic deletion through gene set enrichment analysis provides a rational approach to 
identify potential differences in response to treatments in different cell lines. 
Expression2Kinases (X2K) is a free online analysis tool that provides gene set enrichment 
analysis for any list of genes against known databases of like gene ontology (GO), kinases, 
transcription factors and pathways(http://www.maayanlab.net/X2K/). 
In order to have a better understanding of the disrupted machinery in each cell line, I 
collected the deleted genes of each of the cell lines I used in my research and previous 
research done in our lab, then applied gene set enrichment analysis to have a better 
understanding on what cell functions are mainly influenced in these cell lines.  
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 TNBC/BLBCs have different deleted genes compared to previously used cell lines as 
shown in Table 3. Listed of deleted genes in each cell line was obtained from cancer cell line 
encyclopedia (http://www.broadinstitute.org). 
 Data interpretation of deleted genes for TNBC/BLBC cell lines in comparison to 
other breast cancer cell lines used in previous research provided minute subtle differences 
that might correlate to the reasoning behind the lack of response on the cell lines used in this 
experiment. The output from X2K analysis (Table 4) shows that previous cell lines use 
(MDA-MB-231, MDA-MB-361, and MCF7), have something in common, which is 
enrichment of cell migration, cell motility and cell motion seems to be highly associated with 
the deleted genes list for each. On the other hand, cell lines used in my set of experiment 
showed a variable gene ontology enrichment that have more kinases and phosphatases 
activity in common. This suggest that the previous set of experiments might have a better 
influence on cancer metastasis and the current treatment combinations between S1P and 
DOX or DOC combination might not be as effective in this case. 
 
 
 
 
 
 
 
 
 
 
 
 Table 3: List of deleted genes in TNBC/BLB, MCF-7, MDA-MB-361, and MDA-MB-231 cell Lines 
HCC1599 HCC1143 
 
MDA-MB-468 HCC38 HCC70 HCC1806 HCC1187 DU4475  MCF-7 MDA-MB-231 MDA-MB-361 
PDE4DIP CDK11B MYST4 CDK11B PDE4DIP PDE4DIP DDR2 CABC1 
 
FMN2 CDK11B CDK11B 
ILK PDE4DIP CTBP2 MYO3A CABC1 DDR2 CABC1 FMN2 
 
CTBP2 TNFRSF1B ARNT 
MAML2 CTBP2 ILK MYST4 FMN2 FMN2 ILK FMN2 
 
TCERG1L MYCL1 ILK 
NCAM1 ILK PIK3C2A ILK NLRP3 MYST4 TMEM123 ILK 
 
ILK PDE4DIP MAML2 
BRCA2 TMEM123 NUMA1 TMEM123 MYST4 NLRP6 NCAM1 MAML2 
 
MAML2 PDE4DIP TMEM123 
STAT5A TMEM123 TMEM123 NCAM1 PTEN ILK FLI1 NCAM1  NCAM1 TPR NCAM1 
ALPK2 NCAM1 NCAM1 SORL1 TNKS2 PIK3C2A GUCY2C FLI1  ALPK2 CDC42BPA FLI1 
ADAM17 FLI1 FLI1 FLI1 ILK TMEM123 TSC2 MAPKBP1 
 
ADAM17 CACNB2 GUCY2C 
AAK1 GUCY2C CSNK1G1 GUCY2C TMEM123 NCAM1 ACACA KLK7 
 
AAK1 PCDH15 PIK3C2G 
TNRC6B HSP90B1 ERBB2 PIK3C2G NCAM1 FLI1 ALPK2 AURKC 
 
NCOA3 ILK MAF 
EP300        MAF KLK7 MAF FLI1 PIK3C2G ADAM17 ADAM17 
 
MYH9 PGR KLK7 
TOP2B       KLK7 ADAM17 BRIP1 GUCY2C HSP90B1 AAK1 PAX3  MAML3 TMEM123 ADAM17 
TEC       AAK1 NCOA3 ALPK2 RB1 MAF FN1 EP300  VEGFC MMP1 FN1 
MAML3        FN1 TNRC6B KLK7 BMP4 KLK7 PAX3 MYLK 
 
MAP3K1 NCAM1 PAX3 
VEGFC     NCOA3 CNTN6 ADAM17 WDHD1 ADAM17 MYH9 FGFR3 
 
MAP3K4 NCAM1 EP300 
MAP3K1     CNTN6 BMP2K FN1 MLKL STRADB MAPKAPK3 MAML3 
 
MET PCSK7 FGFR3 
FLT4 MAPKAPK3 MAML3 PAX3 ALPK2 FN1 FGFR3 VEGFC 
  
SORL1 KDR 
MAPK14    MAML3 VEGFC NCOA3 BAX PAX3 TEC CHD1   FLI1 MAML3 
ADAM28    VEGFC MAP3K1 EIF4E KLK7 CARD10 PDGFRA CAMK2A   NCAPD3 VEGFC 
PREX2      CHD1 CHD1 MAML3 STAT1 TNRC6B MAML3 ETV1 
  
  
RECQL4      EDN1 NOTCH4 VEGFC FN1 ROBO2 MSH3 CREB3L2 
  
WNK1 MAP3K1 
GPR112      BRD2 FANCE MAP3K1 PAX3 MAML3 EDN1 ADAM28 
  
GUCY2C CHD1 
 
    TTBK1 GOPC CREB3L2 REM1 VEGFC ETV1 RECQL4 
  
PIK3C2G EDN1 
 
     ETV1 MAP3K4 ADAM28 NCOA3 MAP3K1 PDK4 MLLT3   KRAS BRD2 
 
 CREB3L2 ETV1 GPR112 CARD10 CHD1 CREB3L2 SMC2   ITPR2 DNAH8 
 
 ADAM28 CREB3L2 
 
MAML3 EDN1 EPHB6 AR 
  
LRRK2 CREB3L2 
 
  RECQL4 EPHB6 
 
MYLK MAPK14 ADAM28 
 
  
DYRK2 ADAM28 
 
  GPR112 ADAM28 
 
TEC ETV1 RECQL4 
 
  KSR2 GPR112 
  
RECQL4 
 
PDGFRA ADAM28 GPR112 
 
  
SACS TRRAP 
        
  
  
7
7
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Table 4:  Expression 2 Kinase output for  TNBC/BLBC,MCF-7, MDA-MB-361, and MDA-MB-231 cell Lines 
MCF-7 MDA-MB-361 
Cell migration (GO:0016477) Cell motility (GO:0048870) 
Signal transduction (GO:0007165) Positive regulation of cell migration (GO:0030335) 
Cell motility (GO:0048870) Response to hypoxia (GO:0001666) 
Cell communication (GO:0007154) Regulation of cell size (GO:0008361) 
Cytokinesis (GO:0000910) Positive regulation of cell motion (GO:0051272) 
    
HCC1806 HCC70 
Regulation of cell size (GO:0008361) Protein modification process (GO:0006464) 
Positive regulation of kinase activity (GO:0033674) Positive regulation of caspase activity (GO:0043280) 
Positive regulation of protein kinase activity 
(GO:0045860) Phosphate metabolic process (GO:0006796) 
Positive regulation of transferase activity (GO:0051347) Protein amino acid phosphorylation (GO:0006468) 
Cell migration (GO:0016477) Peptidyl-tyrosine phosphorylation (GO:0018108) 
    
DU4475 HCC1887 
Cytokinesis (GO:0000910) Positive regulation of cell migration (GO:0030335) 
Cell division (GO:0051301) Positive regulation of cell motion (GO:0051272) 
Positive regulation of transcription factor activity 
(GO:0051091) Regulation of cell size (GO:0008361) 
Positive regulation of DNA binding (GO:0043388) Cell migration (GO:0016477) 
Positive regulation of binding (GO:0051099) Regulation of cell migration (GO:0030334) 
    
MDA-MB-468 MDA-MB-231 
Positive regulation of kinase activity (GO:0033674) Positive regulation of cell migration (GO:0030335) 
Positive regulation of protein kinase activity 
(GO:0045860) Positive regulation of cell motion (GO:0051272) 
Positive regulation of transcription (GO:0045941) Cell migration (GO:0016477) 
Positive regulation of transferase activity (GO:0051347) Positive regulation of metabolic process (GO:0009893) 
Positive regulation of gene expression (GO:0010628) Regulation of cell migration (GO:0030334) 
    
HCC143 HCC38 
Regulation of cell size (GO:0008361) Sensory perception of sound (GO:0007605) 
Cell migration (GO:0016477) Cell migration (GO:0016477) 
Spermatogenesis (GO:0007283) Positive regulation of metabolic process (GO:0009893) 
Eicosanoid biosynthetic process (GO:0046456) Positive regulation of transcription (GO:0045941) 
Regulation of blood vessel size (GO:0050880) Positive regulation of gene expression (GO:0010628) 
  
 HCC1599  
Signal transduction (GO:0007165)  
Cell communication (GO:0007154)  
Protein kinase cascade (GO:0007243)  
Response to hypoxia (GO:0001666)  
Response to organic substance (GO:0010033)  
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6. CONCLUSION AND FUTURE DIRECTIONS 
 
The major objective of this project was to investigate whether S1P can induce 
cytotoxicity in TNBC/BLBC cell lines. Our data demonstrated that S1P could induce cell 
death after prolonged exposure in some of the cell lines. Cytotoxicity occurred at a narrow  
range of S1P concentration.  
In proliferation studies, it was found that prolong exposure of S1P can have a 
marginal proliferative effect. The reason for these contradictory results is not clear, however, 
this is an indication that S1P has intracellular and extracellular targets. 
The mechanisms by which S1P induces cell death was observed to be due to apoptosis 
at tested concentrations. The images showed that S1P induced morphological changes, 
shrinkage, and detachment of cells after 72 hr of treatment. 
 The study also aimed to examine the co-administration of S1P with currently used 
chemotherapeutic agents. In this part, results obtained showed a different response than the 
previous studies. The combination showed no significant advantage over the 
chemotherapeutic agents alone and in some cell lines, it attenuated the effect of the drug 
itself. 
We need further investigation about the downstream pathways that triggered an 
apoptotic effect in TNBC/BLBC. An evaluation of the expression of cell surface S1PRs and 
the S1P metabolizing enzyme is eagerly needed to understand better the morphological 
changes after the treatment. This can be done by extracting mRNAs for the S1PRs from 
TNBC/BLBC cell lines and performing quantitative RT-PCR. Assessing the expression of 
S1PR can give more explanation of results obtained from this study. 
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Pharmacological studies using S1PR antagonist maybe used for further understanding 
of S1P function.  Several S1PR receptors antagonists are currently available such as 
VPC23019, which is an S1PR1 antagonist that can be used to block the function of S1PR1, 
and therefore we can test the effect of exogenous S1P on these cell lines. Receptor down 
regulation is another approach for understanding the function. Gene deletion for specific 
S1PR can exclude that the receptor product of the deleted gene mediates an effect. Molecular 
approaches to use microRNA or siRNA to regulate gene expression for S1PR or enzyme 
involved in S1P pathway can also be used to understand the different response of 
TNBC/BLBC to exogenous S1P. Labeled S1P can be used to clarify whether the exogenously 
administered S1P enters the cell and S1P trafficking. 
Further investigation is needed to understand the lack of response in the 
chemotherapy combination studies. Interaction of S1P with chemotherapeutic agents or 
expression level of efflux transporter, P-gp, could explain the results obtained.  
Based on X2K result, I would suggest that combination with tyrosine kinase inhibitors 
might potentially show a more significant synergistic effect when combined to S1P in 
TNBC/BLBC cell lines. 
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